알라우누스 테라퓨틱스

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. The company develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. It also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.